Appili Therapeutics Showcases ATI-1701 Biodefense Advancements
At IDWeek 2024™, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) is set to share groundbreaking advancements regarding their biodefense program, particularly focusing on their tularemia vaccine candidate, ATI-1701. This potential first-in-class vaccine has been a focal point in the fight against tularemia, a disease caused by the highly infectious pathogen F. tularensis.
Unveiling the Efficacy of ATI-1701
Recent preclinical studies have provided encouraging results demonstrating that a single dose of ATI-1701 can effectively protect animal models against lethal tularemia for up to one year post-vaccination. This noteworthy finding positions ATI-1701 as a promising candidate for further clinical development. The company aims to leverage these findings, along with a solid financial backing, to enhance their research trajectory.
Funding Support from Government Agencies
To bolster ATI-1701's development, Appili secured a substantial funding commitment amounting to US$14 million from the United States Air Force Academy, in collaboration with the Defense Threat Reduction Agency. These funds will aid in advancing the vaccine candidate towards an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA) slated for 2025.
Details of the Upcoming Presentation
During the poster presentation at IDWeek, Appili's Chief Development Officer, Dr. Gary Nabors, along with other key members of the scientific team, will outline the manufacturing progress and extensive research underlying ATI-1701. They will detail the compelling results from the 365-day vaccination and challenge study, highlighting the robustness of the vaccine candidate.
Event Details
The presentation is scheduled for October 17, 2024, at 12:15 PM PT / 3:15 PM ET at the Los Angeles Convention Center. Attendees can expect an in-depth exploration of ATI-1701's developmental journey and its critical importance in biodefense.
Appili Therapeutics' Commitment to Infectious Diseases
Appili Therapeutics is dedicated to addressing urgent infectious diseases through innovative biopharmaceutical solutions. Their focus is on developing and advancing therapeutic options that can combat severe infections effectively. Currently, the company is driving a diverse portfolio of anti-infectives, including an FDA-approved product for antimicrobial infections and a topical antiparasitic treatment.
Understanding the Significance of ATI-1701
As a live-attenuated vaccine designed to target F. tularensis, ATI-1701 emerges as a critical player in the medical countermeasure arsenal against potential biological threats, notably due to its classification as a Category A pathogen. With no existing approved vaccine for tularemia available within major markets, the urgency for effective countermeasures is paramount.
About IDWeek 2024™
IDWeek is an essential annual conference that brings together multiple organizations focused on infectious diseases. This year's theme, "Advancing Science, Improving Care," reflects the need for advanced knowledge in the prevention, diagnosis, treatment, and epidemiology of various infectious diseases, including those caused by emerging pathogens.
Frequently Asked Questions
What is ATI-1701?
ATI-1701 is a novel live-attenuated vaccine candidate aimed at preventing tularemia, a highly infectious disease caused by F. tularensis.
How effective is ATI-1701?
Preclinical studies indicate that a single dose of ATI-1701 provides full protection against lethal tularemia in animal models for at least one year.
What funding has Appili received for ATI-1701?
Appili secured a US$14 million commitment from the United States Air Force Academy, facilitating further development of the ATI-1701 program.
When is Appili's presentation at IDWeek 2024?
The poster presentation is scheduled for October 17, 2024, at 12:15 PM PT / 3:15 PM ET.
What is the importance of ATI-1701 in biodefense?
Given its Category A classification as a highly infectious pathogen, the development of ATI-1701 is crucial for biodefense against potential threats.
